# Ascendis Pharma (ASND) — News

ASND · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/asnd/news

## Recent headlines

- [Biomarin: For product includes NavePegritede, Yuviwel](https://www.ainvest.com/news/biomarin-product-includes-navepegritede-yuviwel-2610) — AInvest Wire, Sep 30, 2026
  BioMarin Pharmaceutical Inc. has entered into a licensing agreement with Ascendis Pharma, granting the latter a non-exclusive, worldwide license to use navepegritide, an active ingredient in Ascendis’ recently approved achondroplasia treatment, Yuviwel. Under the terms of the agreement, BioMarin…
- [Ascendis Pharma A/S - All licenses in metabolic and cardiovascular diseases to revert to Ascendis; no continuing financial obligations](https://www.ainvest.com/news/ascendis-pharma-licenses-metabolic-cardiovascular-diseases-revert-ascendis-continuing-financial-obligations-2609) — AInvest Wire, Sep 14, 2026
- [Ascendis Pharma A/S - To regain exclusive rights to transccon technology in metabolic and cardiovascular diseases](https://www.ainvest.com/news/ascendis-pharma-regain-exclusive-rights-transccon-technology-metabolic-cardiovascular-diseases-2609) — AInvest Wire, Sep 14, 2026
  Ascendis Pharma A/S has entered into a strategic collaboration and licensing agreement with Novo Nordisk A/S, granting the latter exclusive worldwide license to its TransCon technology platform for the development and commercialization of products in metabolic and cardiovascular diseases. The…
- [Ascendis announces planned $400 million share repurchase program](https://www.ainvest.com/news/ascendis-announces-planned-400-million-share-repurchase-program-2609) — AInvest Wire, Sep 14, 2026
- [Ascendis Pharma A/S: Oppenheimer raises target price to $312 from $304](https://www.ainvest.com/news/ascendis-pharma-oppenheimer-raises-target-price-312-304-2609) — AInvest Wire, Sep 2, 2026
  Oppenheimer has raised its price target for Ascendis Pharma A/S (NASDAQ:ASND) to $312 from $304, while maintaining an Outperform rating, following settlement with BioMarin Pharmaceutical . The settlement, announced on June 13, resolves all litigation and grants Ascendis a non-exclusive, global…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).